NRx Pharma: Data Safety Monitoring Board Finds No New Safety Concerns In ACTIV-3b Trial

NRx Pharmaceuticals (NRXP) said the Independent Data Safety Monitoring Board found no new safety concerns in the ACTIV-3b Critical Care phase 3 study, after reviewing 231 patients, and recommended continued enrollment. ACTIV-3b is a randomized, placebo-controlled trial testing ZYESAMI and remdesivir - alone and in combination - in hospitalized patients with acute respiratory failure due to COVID-19 who require high-flow supplemental oxygen.

"With this second independent safety analysis in the ACTIV-3b trial, the safety database on ZYESAMI has grown to more than 500 patients. So far, there have been no reports of unexpected, drug-related serious adverse events," said Jonathan Javitt, CEO of NRx.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Cryptocurrency Dogecoin's price jumped over 15% on Friday, but later lost some of the gains, after Tesla Inc. (TSLA) CEO Elon Musk announced that the luxury car maker will start accepting the meme cryptocurrency as payment for its merchandise. "Tesla merch buyable with Dogecoin," Musk tweeted on Friday. Dogecoin... US investment bank JPMorgan Chase & Co. reported Friday a profit for the fourth quarter that declined 14 percent from last year, hurt primarily by higher noninterest expense and lower credit reserve releases. Both adjusted earnings per share and revenues for the quarter topped analysts' expectations. Microsoft Corp. said its Board of Directors has initiated a review of the effectiveness of its workplace sexual harassment and gender discrimination policies and practices. The company has hired the law firm of Arent Fox to conduct the review mainly on sexual harassment investigations, including that of co-founder Bill Gates.
Follow RTT